Collegium Pharmaceutical (COLL) Projected to Post Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is expected to be releasing its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Collegium Pharmaceutical to post earnings of $1.50 per share and revenue of $174.96 million for the quarter. Collegium Pharmaceutical has set its FY 2025 guidance at EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $27.78 on Tuesday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm’s 50-day simple moving average is $28.18 and its 200 day simple moving average is $30.23. The stock has a market cap of $892.63 million, a price-to-earnings ratio of 11.97 and a beta of 0.63. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Analyst Ratings Changes

COLL has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday, March 24th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the sale, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.